AbbVie’s Downward Humira Guidance Worries Analysts
Decreasing Humira’s ex-US sales guidance for the second time in three months caught significant attention, as AbbVie now expects 30% revenue erosion for its top-seller outside its home market.
You may also be interested in...
AbbVie’s product pipeline may be delivering just in time to alleviate concerns about loss of exclusivity on its best-selling product, Humira.
Central to AbbVie’s plans to endure biosimilar erosion to Humira, Skyrizi gets US approval in psoriasis, with approval of upadacitinib expected in RA this year.
First suit challenging biosimilar litigation settlements ratchets up pressure on AbbVie's "patent thicket" and licensing strategy.